CLINICAL TRIALS

The following describes some of the ongoing research in the Division of Immunology and Rheumatology

Dr. Chaichian is the Director of the Stanford Lupus Clinic, which provides longitudinal patient-centered care to patients with all types of systemic lupus erythematosus (SLE). Along with Dr. Mark Genovese, he serves as the Stanford site co-director for the Lupus Clinical Investigators Network (LuCIN). He has been an investigator for several clinical trials in SLE, including the primary investigator at Stanford for a multicenter randomized controlled trial examining a novel therapeutic agent for the treatment of membranous lupus nephritis. He is interested in conducting additional clinical trials evaluating the efficacy and safety of novel therapeutics for SLE to improve the treatment paradigm and outcomes for patients with this diagnosis.

Dr. Chung leads a team of clinicians and researchers focusing on systemic sclerosis (SSc) patient care and research. In addition to providing exceptional care, the center maintains a detailed clinical database and biorepository of tissue samples that are used in collaborative studies. Dr. Chung’s particular research areas of interest include epidemiologic, outcomes, and translational studies on cutaneous, pulmonary, musculoskeletal, gastrointestinal, and reproductive complications of SSc and related connective tissue diseases. The center also conducts industry-sponsored and investigator-initiated clinical trials of novel therapeutic agents for the treatment of SSc and related diseases. Clinical trials include investigations of novel therapeutic agents for the treatment of Raynaud’s phenomenon, cutaneous sclerosis, calcinosis, interstitial lung disease, digital ulcers, pulmonary arterial hypertension, and inflammatory myopathies.

MATT BAKER, MD, MS

Dr. Baker is the co-director of the Stanford Multidisciplinary Sarcoidosis Program and an investigator in the Clinical Trials research group in the Division of Immunology and Rheumatology. In addition to caring for patients, he performs clinical trials, epidemiologic studies, and translational laboratory research. His primary focus includes studies of sarcoidosis, IgG4-related disease, and Sjögren’s syndrome. He has experience designing and implementing investigator initiated clinical trials, and he is particularly interested in identifying novel therapies for patients with these rare diseases. In addition to therapeutic interventions, he is part of a collaborative effort to create a clinical database and biobank in order to better understand disease mechanisms.

MARK GENOVESE, MD, EMERITUS

Dr. Genovese was the founder and director of the Clinical Trials research group in the Division of Immunology and Rheumatology and his research was in the areas of clinical trials, outcomes, and biomarkers. His focus included studies of Rheumatoid Arthritis, Psoriatic Arthritis, and Osteoarthritis. He had extensive experience designing, implementing, coordinating, and evaluating studies, data, and sample collection in autoimmune diseases and osteoarthritis (OA). As a principal investigator on over 100 studies at the Stanford University Medical School, he  was responsible for all aspects of projects, including the initial conceptualization and design of investigator-initiated, as well as multi-center, clinical studies. He previously served as Co-PI of the Stanford site of the NIAID-funded Autoimmunity Center of Excellence (ACE) and of the previously NIAMS-funded TETRAD Network. Therapies under study have included biologic response modifiers such as anti-cytokine therapies and have also included vaccines, oral toleragens, inhibitors of co-stimulation, and small molecule enzyme inhibitors. In addition to clinical investigation focused on therapeutic intervention, further studies have reflected collaborative efforts directed toward the identification of biomarkers and characterization of autoantibody development in the setting of autoimmune diseases.